Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12

Molecular Immunology

Volumn 50, Issue 4, 2012, Pages 193-199

  Karpenko, Larisa I ^a   Scherbakova, Nadezhda S ^a,b   Chikaev, Anton N ^a   Tumanova, Olga Yu ^a   Lebedev, Leonid R ^a   Shalamova, Lyudmila A ^a,b   Pyankova, Olga G ^a   Ryzhikov, Alexander B ^a   Ilyichev, Alexander A ^a,b  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^b NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Broadly neutralizing antibodies 2G12; Peptide mimotope; Phage peptide library; Polyepitope protein; Virus neutralization HIV 1

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY 2G12; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT T CELL AND B CELL IMMUNOGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BINDING SITE; BIOPANNING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOBLOTTING; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PRIORITY JOURNAL; VACCINATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84858343126     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.01.003     Document Type: Article

References (28)

1. Bazhan S.I., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Karpenko L.I., Nekrasova N.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Aborneva I.V., Ilyichev A.A. Designing and engineering of DNA-vaccine construction encoding multiple CTL epitopes of major HIV-1 antigens. Vaccine 2004, 22:1672-1682.
2. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
3. Böttger V., Böttger A. Epitope mapping using phage display peptide libraries. Methods Mol. Biol. 2009, 524:181-201.
4. Casey J.L., Coley A.M., Parisi K., Foley M. Peptide mimics selected from immune sera using phage display technology can replace native antigens in the diagnosis of Epstein-Barr virus infection. Protein Eng. Des. Sel. 2009, 22:85-91.
5. D'souza M.P., Livnat D., Bradac J.A., Bridges S.H., The AIDS clinical trials group antibody selection working group a.C.I. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 1997, 197:1056-1062.
6. Eroshkin A.M., Karginova E.A., Gileva I.P., Lomakin A.S., Lebedev L.R., Kamyinina T.P., Pereboev A.V., Ignat'ev G.M. Design of four-helix bundle protein as a candidate for HIV vaccine. Protein Eng. 1995, 8:167-173.
7. Fack F., Hügle-Dörr B., Song D., Queitsch I., Petersen G., Bautz E.K. Epitope mapping by phage display: random versus gene-fragment libraries. J. Immunol. Methods 1997, 7:43-52.
8. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., Livingston B.D., Villafana T.L., Li H., Noonan E., Russell N.D. HIV Vaccine Trials Network. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope. DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2007, 10:215-223.
9. Karpenko L.I., Ilyichev A.A., Eroshkin A.M., Lebedev L.R., Uzhachenko R.V., Nekrasova N.A., Plyasunova O.A., Belavin P.A., Seregin S.V., Danilyuk N.K., Zaitsev B.N., Danilenko E.D., Masycheva V.I., Bazhan S.I. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine. Design, immunogenicity and toxicity studies. Vaccine 2007, 25:4312-4323.
10. Knittelfelder R., Riemer A.B., Jensen-Jarolim E. Mimotope vaccination - from allergy to cancer. Expert Opin. Biol. Ther. 2009, 9:493-506.
11. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzales J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79(16):10108-10125.
12. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
13. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73:4009-4018.
14. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
15. Menendez A., Calarese D.A., Stanfield R.L., Chow K.C., Scanlan C.N., Kunert R., Katinger H., Burton D.R., Wilson I.A., Scott J.K. A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 2008, 22:1380-1392.
16. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 2009, 485:395-405.
17. Muller S Immunization with peptides. Synthetic Polypeptides as Antigens 1990, 19:131-144. Elsevier Science Publishers B.V., North-Holland, Amsterdam.
18. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8340-8347.
19. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hygiene 1938, 27:493-497.
20. Rosa D.S., Ribeiro S.P., Almeida R.R., Mairena E.C., Postól E., Kalil J., Cunha-Neto E. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One 2011, 11:e16921.
21. Sambrook J., Russel D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory, New York, USA.
22. Scott J.K. Discovering peptide ligands using an epitope library. Science 1992, 17:241-245.
23. Scott J.K., Smith G.P. Searching for peptide ligands with an epitope library. Science 1990, 249:386-390.
24. Sparks A.B., Adey N.B., Cwirla S., Kay B. Phage display of peptides and proteins. A Laboratory Manual 1996, 227-253. Academic, London. B.A. Kay, J. Winter, J. McCafferty (Eds.).
25. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., Weinhold K.J., Ferrari G., Parker S.D., McElrath M.J., Frey S.E., Fuchs J.D., Keefer M.C., Lubeck M.D., Egan M., Braun R., Eldridge J.H., Haynes B.F., Corey L. NIAID HIV vaccine trials network. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 7:243-249.
26. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas C.F., Burton D.R., Ho D.D., Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69:6609-6617.
27. Tumanova O.Yu., Kuvshinov V.N., Il'ichev A.A., Nekrasov B.G., Ivanisenko V.A., Kozlov A.P., Sandakhchiev L.S. Localization of the HIV-1 gp120 conformational epitope recognized by virus-neutralizing monoclonal antibodies 2G12. Mol. Biol. 2001, 36(4):517-521.
28. Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010, 10:527-535.